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INTRODUCTION
The detection and removal of colorectal polyps using colo-
noscopy is the most effective method of preventing colorectal 
cancer (CRC) and CRC-related deaths.
1-5 Patients who have 
undergone colonoscopic polypectomy are at an increased risk 
for CRC and should be placed in a postpolypectomy surveil-
lance program.
2,3,6-11 Postpolypectomy surveillance has become 
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a major component of endoscopic practice because an increas-
ing number of patients with colorectal polyps have been dis-
covered as a result of increased use of CRC screening, particu-
larly the dramatic increase in screening colonoscopies.
12,13 How-
ever, although postpolypectomy colonoscopy surveillance 
could reduce the incidence of CRC and improve CRC-related 
mortality, its preventative effect is smaller than that of screening 
colonoscopies, and there is a need to increase the efficiency of 
surveillance colonoscopy practices and decrease the number 
of unnecessary examinations and their associated costs, risks, 
and the diversion of scarce medical resources.
6,9,14
To this end, postpolypectomy surveillance guidelines have 
been established and revised in several Western countries.
15-21 
Although the incidence of CRC and its precursor, colorectal 
polyps, in South Korea is comparable to those in Western 
countries,
22,23 Korea-specific practical guidelines for postpol-
ypectomy surveillance are not currently available. Thus, there 
is a need for practical guidelines that reflect epidemiological 
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characteristics of the Korean population and medical environ-
ment in Korea. To achieve this goal, the Korean Society of Gas-
troenterology (KSG), the Korean Society of Gastrointestinal 
Endoscopy (KSGE), the Korean Association for the Study of 
the Intestinal Diseases and the Korean Society of Abdominal 
Radiology organized a multi-society taskforce for a guideline 
for colorectal polyp screening, surveillance and management 
in order to review and analyze previous researches thus far and 
suggest the first Korean evidence-based practical guideline that 
can be used as a reference for postpolypectomy surveillance. 
However, this practical guideline cannot override the clinical 
judgments made by practicing physicians. In addition, this first 
Korean guideline should be revised and supplemented in the 
future as new evidences become available.
Purpose
The present guideline is designed as a patient care reference 
that will support physicians who are responsible for patients 
with colorectal polyps and for conducting colonoscopies in 
clinical practice. In the present report, a careful analytic approach 
was designed to address all of the available evidence in the lit-
erature that delineates predictors of advanced neoplasms, both 
cancers and advanced adenomas, with the aim of risk stratify-
ing patients based on their index colonoscopy. However, the 
available Korean studies were not sufficient; therefore, expert 
opinions were collected using an internet survey and a Delphi 
meeting to represent the characteristics of the Korean popula-
tion and the medical environment in Korea.
Necessity 
Asymptomatic persons aged 50 years or older who are con-
cerned about the possible presence of CRC are advised to re-
ceive CRC screening colonoscopies. Because the risk of future 
CRC is increased in patients who have undergone polyp remov-
al, it is recommended that these patients participate in a peri-
odic surveillance program.
15,16,18-20,24 Korean society is aging rap-
idly, according to the population forecasts of the Korean Na-
tional Statistical Office. The proportion of the population aged 
50 or over (i.e., the population that may require CRC screening 
colonoscopies) is expected to rapidly increase from 29% in 2010 
to 40% in 2020, and to 60% in 2050,
25 but the number of ex-
perts and facilities available to conduct colonoscopies cannot 
increase indefinitely. Therefore, to make efficient use of limited 
medical resources, surveillance colonoscopy intervals should 
be scheduled so as to shift available resources from intensive 
surveillance to screening. This effort can also prevent the in-
crease in medical expenditures and complications associated 
with unnecessary surveillance. 
Limitations 
Most of the systematically identified studies used as evidence 
in the present report were performed in Western countries, 
and the number of studies performed in Korea was limited. 
Therefore, the taskforce undertook web-based surveys to ascer-
tain current Korean clinical practices and a Delphi meeting with 
clinical experts to explore the level of agreement on the initial 
practical guideline proposal. In addition, because most of the 
studies used evidence from observational studies rather than 
randomized controlled trials, the quality of evidence for this 
guideline was generally graded as low. 
Guideline development teams and development 
processes
To develop this guideline, a multi-society taskforce consist-
ing of experts recommended by the KSG, the KSGE, the Ko-
rean Association for the Study of the Intestinal Diseases and 
the Korean Society of Abdominal Radiology was established in 
June 2010. There were no conflicts of interest for any of the par-
ticipating members.
Distribution of the guideline and implementing 
activities
The developed guideline will be co-published in the journals 
of the KSG, the KSGE, the Korean Association for the Study 
of Intestinal Disease (KASID) and the Journal of the Korean 
Society of Radiology. The guideline will also be published th-
rough the websites of the relevant societies and in major medi-
cal newspapers. Additionally, the contents will be widely dis-
tributed through a summary guidebook to training hospitals. 
Feedback after the guideline implementation and 
revisions
After a certain amount of time has passed after the distribu-
tion and implementation of the guidelines, adherence to the 
guideline in clinical practice will be assessed. Furthermore, the 
contents will be periodically revised to reflect the latest clinical 
knowledge.
METHODS
Definitions 
The medical terms related to colonoscopic surveillance in this 
guideline were chosen to be consistent with the terms used in 
previous studies.
1) Postpolypectomy surveillance: Periodic examination of the 
colon to detect synchronous or metachronous neoplasia after 
polypectomy. This term does not include the use of colonosco-
py or other procedures to monitor for polyp or cancer recur-
rence following a diagnosis of CRC.46  Clin Endosc 2012;45:44-61
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2) Advanced adenoma: An adenoma of 10 mm or larger, an 
adenoma with high-grade dysplasia, or an adenoma containing 
25% or more villous components.
3) Advanced neoplasia: An advanced adenoma or invasive 
cancer. 
4) Index colonoscopy: The colonoscopy conducted most re-
cently prior to the surveillance colonoscopy. The index colo-
noscopy should be performed according to the quality guide-
line of CRC screening recommended by the Ministry of Health 
and Walfare.
26 
5) Index adenoma: The largest adenoma found in an index 
colonoscopy. If all of the adenomas are smaller than 10 mm, 
the index adenoma refers to any adenoma that contains high-
grade dysplasia or 25% or more villous components. 
Although the incidence of CRC and CRC-related mortali-
ty are ideal outcome measures for evaluating the effectiveness 
of postpolypectomy surveillance, they are not practical to use 
because they require lengthy follow-up. Thus, advanced neo-
plasia, which includes both advanced adenoma and invasive 
cancer, has commonly been adopted as a surrogate biological 
marker for CRC.
1,21
Key questions 
The following key questions were selected for constructing 
postpolypectomy colonoscopic surveillance guidelines. 1) What 
are the risk factors for subsequent advanced neoplasia that 
must be considered when determining the colonoscopy sur-
veillance interval? 2) Based on these risk factors, how can pa-
tients with a high risk of subsequent advanced neoplasia be 
identified? 3) What is the optimal colonoscopy surveillance in-
terval in patients without risk factors for subsequent advanced 
neoplasia? 4) What is the optimal colonoscopy surveillance in-
terval in patients with a high risk of subsequent advanced neo-
plasia? 
Literature search
The literature review process began with a systematic MED-
LINE, Cochrane Library and National Guideline Clearing-
house search for guidelines addressing surveillance colonosco-
py after endoscopic resection of colorectal polyps that were 
published between 2000 and 2010. Both the postpolypectomy 
colonoscopic surveillance guidelines of the US Multi-Society 
Task Force on Colorectal Cancer and the American Cancer So-
ciety (USMSTF-ACS)
21 and the European Panel on the Appro-
priateness of Gastrointestinal Endoscopy guidelines for surveil-
lance after colorectal polyp and CRC excision
15 included 
evidence tables. The studies included in these evidence tables 
were reviewed. 
For the systematic literature review, electronic databases, 
including MEDLINE and the Cochrane Library, were searched 
from January 2000 and September 2010 to identify potentially 
relevant English-language articles. The keywords used in the 
English searches were “colonoscopy” AND “colon OR colonic 
OR colorectal” AND “polyp OR neoplasm OR neoplasia.” Stud-
ies that were published in Korean were identified using the Ko-
rean Studies Information Service System (http://kiss.kstudy.
com) and the Korean Medical Database (http://kmbase.med-
ric.or.kr). The keywords used in Korean literature searches were 
“colonoscopy” AND “colorectal polyp” or “colonoscopy” AND 
“large intestinal polyps.” The studies were included if they met 
the following criteria: 1) the manuscript was written in Korean 
or English; 2) the full manuscript was available; 3) the study 
was published between 1991 and 2010; 4) a cohort study, ran-
domized controlled trial and pooled analysis study design was 
used; 5) the study participants were 18 years old or older with 
at least one colorectal polyp; 6) the intervention was defined as 
surveillance colonoscopy conducted for 6 months or longer 
after the index colonoscopy; and 7) the results included the in-
cidence of subsequent advanced neoplasia at the surveillance 
colonoscopy, risk factors for subsequent advanced neoplasia, 
and colonoscopic surveillance interval. The studies conducted 
on patients with Lynch syndrome (hereditary non-polyposis 
CRC), familial polyposis, inflammatory bowel disease or CRC 
were excluded. The eligible articles were independently reviewed 
by the two taskforce members (H.S.N. and Y.D.H.). A total of 
884 English references and 391 Korean references were identi-
fied using this search strategy. The article abstracts were indi-
vidually evaluated for inclusion. The complete texts were ob-
tained for the articles that were deemed potentially relevant. In 
addition, a manual recursive search of the reference sections of 
the selected studies was performed to identify other poten-
tially relevant articles. In total, 833 English articles and 389 Ko-
rean articles were excluded from the initial literature pool, and 
the remaining 51 English articles and 3 Korean articles were 
selected for inclusion. The full manuscripts of these papers were 
reviewed in detail to prepare a standardized evidence table cor-
responding to the key questions outlined above. When the full 
manuscripts of the papers were reviewed, one additional paper 
that met the literature selection criteria was found in the cited 
references and was included in the selected literature after its 
full text was reviewed. In addition, a large-scale prospective co-
hort study conducted with a Korean population was published 
after the search period; this study was included in the selected 
literature (Fig. 1). 
Meta-analysis
Among the reviewed studies, 17 presented the adjusted 
odds ratio (OR), adjusted relative risk (RR) or hazard ratio 
(HR) and 95% confidence intervals (95% CI) for one or more 
of the risk factors for subsequent advanced neoplasia during DH Yang et al. 
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postpolypectomy colonoscopic surveillance and were included 
in a meta-analysis (Supplementary Table 1 online). Since 
pooled analysis is a study that is provided with unprocessed 
data from the individual studies, a pooled analysis was in-
cluded in the meta-analysis, whereas individual studies were 
excluded from the meta-analysis. The studies that were ini-
tially designed as randomized controlled trials but lost the 
randomized effect when the data were extracted (because the 
case group and the control group were considered as a single 
cohort) were evaluated as observational studies. Because clini-
cal heterogeneity in the study subjects, study designs, periods 
of colonoscopic surveillance and endpoint definitions was 
present among the studies selected for the meta-analysis, a 
random-effects model was applied. The pooled estimates were 
calculated using the inverse variance weighted estimation 
method to measure efficacy. Because RRs are evaluated more 
conservatively in effects estimations than in ORs, and because 
they are close to ORs in cases where disease prevalences are 
low, the results were presented as pooled estimated ORs for 
the studies that presented adjusted ORs and adjusted RRs
27 
and as pooled estimated HRs for the studies that reported 
HRs that were statistically analyzed in terms of time to the 
occurrence of the event. The results of the Cochran’s Q-test 
indicated that the data were statistically heterogeneous 
(p<0.1). The meta-analysis was conducted using Review Man-
ager version 5.1 (The Cochrane Collaboration, Oxford, UK)
Quality of evidence and strength of 
recommendations
Recommendations are presented based on a systematic re-
view of the selected literature and meta-analyses. The quality 
of evidence, indicating the degree to which each recommen-
dation has scientific evidence, and the strength of the recom-
mendations were determined following the methodology 
proposed by the Grading of Recommendations Assessment, 
Development and Evaluation Working Group (Table 1).
28,29
The quality of evidence was assessed to be “high” when evi-
dence consisted of randomized controlled trials and “low” in 
Potentially relevant studies identified by search strategy (n=1,275)
Studies searched in MEDLINE, Cochrane Library or referred in previous guideline (n=884)
Studies searched in Koreanstueies Information Service System or Korean Medical Database (n=391)
Trials excluded after review of abstract or selected
  review of full tect (n=1,222)
Trials excluded in meta-analysis (n=37)
Duplicate study population (n=13)
Advanced adenoma prevalence not reported (n=8)
Relative risk, odds ratio or hazard ration not repored (n=13)
Study using sigmoidoscopy (n=3)
Trial included in meta-analysis (n=2)
Recursive search of the reference sections (n=1)
Recent published study for Korean (n=1)
Trials obtained for detailed review (n=54)
Trials selected for inclusion in meta-analysis (n=17)
Fig. 1. Flow chart outlining search pro-
cess used to identify articles for inclusion 
in systematic review and meta-analysis.
Table 1. Quality of Evidence and Strength of a Recommendation
Quality of evidence
High quality  Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality  Further research is likely to have an important impact on our confidence 
  in the estimate of effect and may change the estimate.
Low quality  Further research is very likely to have an important impact on our confidence in the estimate 
  of effect and is likely to change the estimate.
Very low quality  Any estimate of effect is very uncertain.
Strength of a recommendation
Strong recommendation Most or all individuals will be best served by the recommended course of action.
Weak recommendation Not all individuals will be best served by the recommended course of action. There is a need 
  to consider more carefully than usual individual patient’s circumstances, preferences, and values.48  Clin Endosc 2012;45:44-61
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cases where evidence included observational studies. However, 
in cases where studies used as evidence had limitations in the 
study design or execution, inconsistent results, indirect evidence, 
imprecise results or publication bias, the quality of evidence was 
adjusted downward. In cases of observational studies where 
large effects were observed, where reported effects might have 
been reduced due to confounding variables or where dose-re-
sponse gradients existed, the quality of evidence was adjusted 
upward. The strength of each recommendation was assessed 
as “strong” or “weak” by considering the balance of desirable 
and undesirable consequences, the quality of the evidence, the 
confidence in the values and the references and the effective al-
location of medical expenses and resources. That is, in cases 
where it was judged that following a specific recommendation 
would lead to significant health benefits or losses for most pa-
tients, the strength of the recommendation was classified as 
“strong.” The strength of the recommendation was classified as 
“weak” in cases where it was judged that following the recom-
mendation would lead to important benefits or loss in terms 
of the quality of the health of patients but where differences ex-
isted among patients, thus leading to the need to consider in-
dividual environments, preferences and values.
28,29
POSTPOLYPECTOMY COLONOSCOPIC 
SURVEILLANCE GUIDELINES
The colonoscopy surveillance intervals recommended in this 
postpolypectomy colonoscopic surveillance guideline were de-
termined according to an evaluation of the risk factors for sub-
sequent advanced neoplasia, including the characteristics of the 
polyps found in the index colonoscopy and other patient char-
acteristics: 
The risk factors for subsequent advanced neoplasia
Does the risk of subsequent advanced neoplasia increase de-
pending on the number of adenomas in the index colonoscopy?
Patients with three or more adenomas have an increased 
risk of subsequent advanced neoplasia.
·Quality of evidence: high 
· Level of agreement: completely agree (74%), generally 
agree (24%), partially agree (3%), generally disagree 
(0%), and totally disagree (0%)
Nine observational studies, including one pooled analysis
30 
and two Korean studies,
9,10,30-36 evaluated the risk of subsequent 
advanced neoplasia based on the number of adenomas found 
in the index colonoscopy (Supplementary Table 2 online). Al-
though statistical heterogeneity among the studies existed, 
the risk of subsequent advanced neoplasia increased when 
the number of adenomas increased, with a pooled OR of 1.93 
(95% CI, 1.51 to 2.45) and a pooled HR of 2.20 (95% CI, 1.49 
to 2.90) (Fig. 2.1.1, 2.2.1). Although the risk of subsequent 
advanced neoplasia did not significantly increase in the pa-
tients with ≥2 adenomas compared to the patients with one 
adenoma (pooled OR, 2.18; 95% CI, 0.86 to 5.54) (Fig. 
2.1.2),
32,33 the risk of subsequent advanced neoplasia signifi-
cantly increased in the patients diagnosed with ≥3 adenomas, 
with a pooled OR of 2.84 (95% CI, 1.26 to 6.39) and a pooled 
HR of 2.20 (95% CI, 1.40 to 3.46) (Fig. 2.1.3, 2.2.2). 
Similar to the results of the meta-analysis, the patients in a 
Korean prospective cohort study with ≥3 adenomas showed 
an increased risk of subsequent advanced neoplasia, with an 
adjusted HR of 3.06 (95% CI, 1.51 to 6.57), compared with the 
patients diagnosed with ≥2 adenomas.
36 A pooled analysis of 
eight large-scale North American randomized controlled trials 
and prospective cohort studies showed that the number of ad-
enomas found in the index colonoscopy, along with patient age, 
was the most significant factor predicting the risk of subse-
quent advanced neoplasia.
30 A dose-response relationship be-
tween the risk of subsequent advanced neoplasia and the num-
ber of adenomas was observed (p for trend <0.0001).
30 When 
the number of adenomas diagnosed in the index colonoscopy 
was ≥5, the OR of the risk of subsequent advanced neoplasia 
increased to 3.87 (95% CI, 2.76 to 5.42).
30 Another meta-anal-
ysis analyzed 4 randomized controlled trials in which the sur-
veillance colonoscopy was conducted at 3 years. Similar to the 
results of the present analysis, the pooled RR for the recurrence 
of advanced neoplasms at 3 years in the patients with ≥3 ade-
nomas was 2.52 (95% CI, 1.07 to 5.97) with respect to that of 
the patients with 1 to 2 adenomas.
37 
By contrast, several studies have reported that polyp miss 
rates significantly increase as the number of polyps found in 
the index colonoscopy increases.
38-42 Kim et al.
41 have reported 
that the risk of missing polyps increased significantly in pa-
tients with ≥5 polyps, with an OR of 4.48 (95% CI, 1.91 to 
10.5). However, most of the missed polyps were non-advanced 
adenomas or non-neoplastic polyps.
39,42-45 Therefore, when a 
high-quality colonoscopy is performed, a long interval will be 
required for any of the missed polyps to become malignant.
46-48 
In addition, previously published guidelines have recom-
mended shortening the colonoscopy surveillance interval in 
patients with multiple polyps. The British Society of Gastroen-
terology/Association of Coloproctology for Great Britain and 
Ireland recommends performing a surveillance colonoscopy 
at 1 year in patients with ≥5 adenomas or ≥3 adenomas in-
cluding at least one that is ≥1 cm,
17 and the USMSTF-ACS rec-
ommends conducting a surveillance colonoscopy within 3 
years in patients with ≥10 adenomas.
21 DH Yang et al. 
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Study or subgroup Log (odds ratio) SE Weight
Odds ratio
IV, random, 95% CI
Odds ratio
IV, random, 95% CI
2.1.1 Overall
Noshirwani et al.,31 (per 1 ↑) 2000 0.2231 0.0515 13.1% 1.25 (1.13, 1.38)
Jorgensen et al.,9 (2) 0.2624 0.4267 05.1% 1.30 (0.56, 3.00)
Martinez et al.,30 (2) 2009 0.3293 0.0906 12.5% 1.39 (1.16, 1.66)
Bonithon-Kopp et al.,49 (2) 0.3365 0.4690 04.6% 1.40 (0.56, 3.51)
Pinsky et al.,34 (≥3 small TA) 2009 0.4055 0.3207 07.0% 1.50 (0.80, 2.81)
Nusko et al.,32 (≥2) 2002 0.4318 0.1631 10.9% 1.54 (1.12, 2.12)
Martinez et al.,30 (3) 2009 0.6152 0.1208 11.9% 1.85 (1.46, 2.34)
Martinez et al.,30 (4) 2009 0.8796 0.1756 10.6% 2.41 (1.71, 3.40)
Jorgensen et al.,9 (≥3) 1.0986 0.4675 04.6% 3.00 (1.20, 7.50)
Bonithon-Kopp et al.,49 (≥3) 1.2809 0.4011 05.5% 3.60 (1.64, 7.90)
Marinez et al.,30 (≥5) 2009 1.3533 0.1725 10.6% 3.87 (2.76, 5.43)
Kim et al.,33 (≥2) 2004 1.4271 0.5676 03.5% 04.17 (1.37, 12.67)
Subtotal (95% CI) 100.0% 1.93 (1.51, 2.45)
Heterogeneity: Tau2=0.11; chi2=64.07, df=11 (p<0.00001); I2=83%
Test for overall effect: z=5.32 (p<0.00001)
2.1.2 1 vs. ≥2
Nusko et al.,32 (≥2) 2002 0.4318 0.1631 64.9% 1.54 (1.12, 2.12)
Kim et al.,33 (≥2) 2004 1.4271 0.5676 35.1% 4.17 (1.37, 12.67)
Subtotal (95% CI) 100.0% 2.18 (0.86, 5.54)
Heterogeneity: Tau2=0.32; chi2=2.84, df=1 (p=0.09); I2=65%
Test for overall effect: z=1.64 (p=0.10)
2.1.3 1 vs. ≥3
Martinez et al.,31 (≥3) 2001 0.01 0.3735 27.0% 1.01 (0.49, 2.10)
Jorgensen et al.,9 (≥3) 1.0986 0.4675 24.0% 3.00 (1.20, 7.50)
Bonithon-Kopp et al.,49 (≥3) 1.2809 0.4011 26.1% 3.60 (1.64, 7.90)
Winawer et al.,6 (≥3) 1993 1.9315 0.498 23.0% 6.90 (2.60, 18.31)
Subtotal (95% CI)       100% 2.84 (1.26, 6.39)
Heterogeneity: Tau2=0.49; chi2=11.00, df=3 (p=0.01); I2=73%
Test for overall effect: z=2.53 (p=0.01)
Test for subgroup defferences: chi2=0.85, df=2 (p=0.65), I2=0%       0.01            0.1                 1                 10              100
Study or subgroup
Log 
(hazard ratio)
SE Weight
Hazard ratio
IV, random, 95% CI
Hazard ratio
IV, random, 95% CI
2.2.1 Overall
Huang et al.,35 (≥3) 0.6259 0.2615 42.0% 1.87 (1.12, 3.12)
Huang et al.,35 (2) 0.6523 0.3128 29.4% 1.92 (1.04, 3.54)
Bertario et al.,10 (≥2) 0.6931 0.5432 9.7% 2.00 (2.69, 5.80)
Chung et al.,36 (≥3) 1.1184 0.3898 18.9% 3.06 (1.43, 6.57)
Subtotal (95% CI) 100.0% 2.08 (1.49, 2.90)
Heterogeneity: Tau2=0.00; chi2=1.22, df=3 (p=0.75); I2=0%
Test for overall effect: z=4.33 (p<0.0001)
2.2.2 1 vs. ≥3
Huang et al.,35 (≥3) 0.6259 0.2615 67.2% 1.87 (1.12, 3.12)
Chung et al.,36 (≥3) 1.1184 0.3898 32.8% 3.06 (1.43, 6.57)
Subtotal (95% CI) 100.0% 2.20 (1.40, 3.46)
Heterogeneity: Tau2=0.01; chi2=1.10, df=1 (p=0.29); I2=9%
Test for overall effect: z=3.41 (p=0.0007)
      0.01            0.1                 1                 10              100
Test for subgroup differences: chi2=0.04, df=1 (p=0.85), I2=0% Favours multiple                         Favours single
Fig. 2. Forest plot for the number of colorectal adenomas as a risk factor for advanced neoplasia. CI, confidence interval.50  Clin Endosc 2012;45:44-61
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Study or subgroup Log (odds ratio) SE Weight
Odds ratio
IV, random, 95% CI
Odds ratio
IV, random, 95% CI
3.1.1 Overall
Bonithon-Kopp et al.49 (≥10 mm) 0.0583 0.3441 8.4% 1.06 (0.54, 2.08)
Martinez et al.30 (5-10 mm), 2009 0.1570 0.1063 14.9% 1.17 (0.95, 1.44)
Jorgensen et al.9 (6-10 mm) 0.1823 0.4502 06.3% 1.20 (0.50, 2.90)
Jorgensen et al.9 (>10 mm) 0.1823 0.4502 06.3% 1.20 (0.50. 2.90)
Pinsky et al.34 (≥10 mm TA), 2009 0.4055 0.2181 11.8% 1.50 (0.98, 2.30)
Nusko et al.32 (>10 mm), 2002 0.5933 0.1244 14.4% 1.81 (1.42, 2.31)
Martinez et al.30 (10-20 mm), 2009 0.8198 0.1072 14.8% 2.27 (1.84, 2.80)
Martinez et al.30 (≥20 mm), 2009 1.0953 0.1485 13.8% 2.99 (2.24, 4.00)
Norshiwani et al.31 (≥10 mm), 2000 1.3029 0.3103 09.3% 3.68 (2.00, 6.76)
Subtotal (95% CI) 100.0% 1.78 (1.34, 2.37)
Heterogeneity: Tau2=0.13; chi2=42.79, df=8 (p<0.00001); I2=81%
Test for overall effect: z=4.00 (p<0.0001)
3.1.2 <5 mm vs. 5-10 mm
Martinez et al.30 (5-10 mm), 2009 0.1570 0.1063 94.7% 1.17 (0.95, 1.44)
Jorgensen et al.9 (6-10 mm) 0.1823 0.4502 05.3% 1.20 (0.50, 2.90)
Subtotal (95% CI) 100.0% 1.17 (0.96, 1.43)
Heterogeneity: Tau2=0.00; chi2=0.00, df=1 (p=0.96); I2=0%
Test for overall effect: z=1.53 (p=0.13)
3.1.3 <10 mm vs. ≥10 mm
van Stolk et al.50 (≥10 mm), 1998 -0.713 0 0.5742 09.9% 0.49 (0.16, 1.51)
Bonithon-Kopp et al.49 (≥10 mm) 0.0583 0.3441 17.7% 1.06 (0.54, 2.08)
Pinsky et al.34 (≥10 mm TA), 2009 0.4055 0.2181 24.1% 1.50 (0.98, 2.30)
Nusko et al.32 (>10 mm), 2002 0.5933 0.1244 28.9% 1.81 (1.42, 2.31)
Norshiwani et al.31 (≥10 mm), 2000 1.3029 0.3103 19.3% 3.68 (2.00, 6.76)
Subtotal (95% CI) 100.0% 1.59 (1.04, 2.43)
Heterogeneity: Tau2=0.15; chi2=13.33, df=4 (p=0.010); I2=70%
Test for overall effect: z=2.12 (p=0.03)
Test for subaroup differences: chi2=6.05, df=2 (p=0.05), I2=66.9%     0.01            0.1                1                  10              100
Study or subgroup
Log 
(hazard ratio)
SE Weight
Hazard ratio
IV, random, 95% CI
Hazard ratio
IV, random, 95% CI
3.2.1 <10 mm vs. ≥10 mm
Huang et al.35 (10-19 mm) 0.2231 0.3776 35.5% 1.25 (0.60, 2.62)
Bertario et al.10 (10-20 mm) 0.6419 0.6811 16.6% 1.90 (0.50, 7.22)
Chung et al.36 (≥10 mm) 1.1053 0.2640 47.9% 3.02 (1.80, 5.07)
Subtotal (95% CI) 100.0% 2.04 (1.10, 3.80)
Heterogeneity: Tau2=0.14; chi2=3.73, df=2 (p=0.16); I2=46%
Test for overall effect: z=2.27 (p=0.02)
    0.01            0.1                 1                 10              100
Favours larger                              Favours smaller
Fig. 3. Forest plot for the size of colorectal adenomas as a risk factor for advanced neoplasia. CI, confidence interval.DH Yang et al. 
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Does the risk of subsequent advanced neoplasia increase depend-
ing on the size of the index adenoma(s)?
Patients with an adenoma that is 1 cm or larger have an 
increased risk of advanced neoplasia.
·Quality of evidence: moderate 
· Level of agreement: completely agree (59%), generally 
agree (35%), partially agree (5%), generally disagree 
(0%), and totally disagree (0%)
Eight observational studies, including one pooled analysis
30 
and one Korean study, have evaluated the risk of subsequent 
advanced neoplasia based on the sizes of the index adenomas 
(Supplementary Table 3 online).
9,10,31,32,34-36,49 In most studies, 
the polyp size was evaluated during colonoscopy.
6,31,49-53 Al-
though statistical heterogeneity existed among the studies, the 
risk of subsequent advanced neoplasia increased as the sizes of 
index adenomas increased, with a pooled OR of 1.78 (95% 
CI, 1.34 to 2.37) (Fig. 3.1.1). Although the risk of subsequent 
advanced neoplasia did not significantly increase in the patients 
with 5 to 10 mm adenomas compared to the patients with ≤5 
mm adenomas (pooled OR, 1.17; 95% CI, 0.96 to 1.43) (Fig. 
3.1.2),
9,30 the risk of subsequent advanced neoplasia significantly 
increased in the patients with ≥10 mm adenomas compared 
to the patients with <10 mm adenomas (Fig. 3.1.3, 3.2.1), 
with a pooled OR of 1.59 (95% CI, 1.04 to 2.43) and a pooled 
HR of 2.04 (95% CI, 1.10 to 3.80). 
Similar results have been found in a Korean prospective co-
hort study in which the HR of the subsequent advanced neo-
plasia in the patients with ≥10 mm adenomas was 3.02 (95% 
CI, 1.80 to 5.06).
36 In a pooled analysis by Martinez et al.,
30 the 
risk of subsequent advanced neoplasia increased as the sizes of 
the adenomas increased (p for trend <0.0001). 
Large adenomas have an increased probability of containing 
areas with advanced histology, including villous or high-grade 
dysplasia and carcinoma. Previous studies have reported that 
the likelihood of a ≥20 mm adenoma containing an area of car-
cinoma may be as high as 32%.
54,55 Large (20 mm or larger) ses-
sile polyps are difficult to remove en bloc using traditional snare 
polypectomy. Although they can be resected en bloc using en-
doscopic submucosal dissection (ESD), ESD requires skilled en-
doscopists and is associated with serious complications, includ-
ing perforation rates as high as 6.2% to 10%.
55-57 Therefore, large 
sessile polyps are often removed using a piecemeal method in 
clinical practice.
56,57 When piecemeal resection has been con-
ducted, however, it is impossible to pathologically assess if there 
has been complete resection, and local recurrences in regions 
where polyps have been resected are reported to be as high as 
12% to 55%.
55,58-61 Therefore, current guidelines recommend 
that patients with large sessile adenomas that have been re-
moved by the piecemeal method should be considered for fol-
low-up evaluations in 2 to 6 months to verify complete remov-
al.
15-18,21
Is the risk of subsequent advanced neoplasia greater in patients 
with tubulovillous or villous adenomas than in patients with 
tubular adenomas only? 
Patients with tubulovillous or villous adenomas have an 
increased risk of advanced neoplasia.
· Quality of evidence: low 
· Level of agreement: completely agree (26%), generally 
agree (53%), partially agree (16%), generally disagree 
(5%), and totally disagree (0%)
Seven observational studies, including one pooled analysis
30 
and one Korean study, assessed the risk of subsequent ad-
vanced neoplasia after tubulovillous or villous adenoma resec-
tion (Supplementary Table 4 online).
9,10,31,34,36,49,62 In most of 
these studies, a tubulovillous or villous adenoma was defined as 
a case in which the villous components in the index adenoma 
exceeded 20% to 25%. A meta-analysis showed that patients 
with tubulovillous or villous adenomas have a greater risk of 
subsequent advanced neoplasia than do patients with only tu-
bular adenomas, with a pooled OR of 1.51 (95% CI, 1.16 to 1.97) 
and pooled HR of 1.83 (95% CI, 1.15 to 2.89) (Fig. 4). 
In a Korean prospective cohort studies, by contrast, the pa-
tients with villous or tubulovillous adenomas did not have an 
increased risk of subsequent advanced adenoma (HR, 1.48; 
95% CI, 0.74 to 2.95).
36 In a Chinese population-based study 
using sigmoidoscopy, the patients with tubulovillous or villous 
adenomas were found to be at increased risk for subsequent 
advanced neoplasia (OR, 8.1; 95% CI, 4.2 to 15.6).
63 Bertario et 
al.
10 and Martinez et al.
51 have separately assessed the risks of 
subsequent advanced neoplasia in patients with tubulovillous 
adenomas and villous adenomas and compared their risk to 
that of patients with only tubular adenomas. These authors did 
not find any significant differences in the risk of subsequent 
advanced neoplasia. 
Is the risk of subsequent advanced neoplasia increased in pa-
tients with high-grade dysplasia adenomas compared with pa-
tients with low-grade dysplasia adenomas?
Patients with high-grade dysplasia adenomas have an in-
creased risk of subsequent advanced neoplasia.
· Quality of evidence: low 
· Level of agreement: completely agree (34%), generally 
agree (55%), partially agree (11%), generally disagree 
(0%), and totally disagree (0%)
After Atkin et al.
11 reported that patients with high-grade dys-
plasia adenomas had a higher risk of colon and rectal cancer 52  Clin Endosc 2012;45:44-61
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in 1992, one pooled analysis and four observational studies
9,10,35,49 
have reported an association between the diagnosis of adeno-
ma with high-grade dysplasia and the risk of subsequent ad-
vanced neoplasia upon colonoscopic surveillance (Supple-
mentary Table 5 online). A meta-analysis of these studies 
revealed that patients diagnosed with high-grade dysplasia 
adenomas in the index colonoscopy have increased risk of 
subsequent advanced neoplasia upon surveillance colonoscopy, 
with a pooled OR of 1.33 (95% CI, 0.85 to 2.09) (Fig. 5.1.1) 
and pooled HR of 1.69 (95% CI, 1.14 to 2.50) (Fig. 5.2.1). 
By contrast, a pooled analysis by Martinez et al.
30 has shown 
that the risk of subsequent advanced neoplasia in patients with 
high-grade dysplasia adenomas was not increased compared 
with patients with low-grade dysplasia adenomas (pooled OR, 
Fig. 4. Forest plot for villous/tubulovillous adenomas as a risk factor for advanced neoplasia. CI, confidence interval, TA, tubular adenoma.
Study or subgroup Log (odds ratio) SE Weight
Odds ratio
IV, random, 95% CI
Odds ratio
IV, random, 95% CI
4.1.1 TA vs. VA/TVA
Jorgensen et al.,9 1995 0.1823 0.4137 009.0% 1.20 (0.53, 2.70)
Martinez et al.30 (pooled analysis) 0.2469 0.0914 043.2% 1.28 (1.07, 1.53)
Noshirwani et al.,31 2000 0.3148 0.3308 012.9% 1.37 (0.72, 2.62)
Bonithon-Kopp et al.49 0.5128 0.4017 009.5% 1.67 (0.76, 3.67)
Pinsky et al.,34 2009 0.7885 0.1954 025.5% 2.20 (1.50, 3.23)
Subtotal (95% CI) 100.0% 1.51 (1.16, 1.97)
Heterogeneity. Tau2=0.03; chi2=6.64, df=4 (p=0.16); I2=40%
Test for overall effect: z=3.03 (p=0.002)
    0.01            0.1                 1                 10              100
Study or subgroup
Log 
(hazard ratio)
SE Weight
Hazard ratio
IV, random, 95% CI
Hazard ratio
IV, random, 95% CI
4.2.1 TA vs. VA/TVA
Bertario et al.10 (V) 0.1823 1.0919 004.6% 01.20 (0.14, 10.20)
Chung et al.,36 2011 0.3920 0.3536 043.8% 1.48 (0.74, 2.96)
Bertario et al.10 (TV) 0.4055 0.6744 012.0% 1.50 (0.40, 5.63)
Huang et al.,35 2010 0.9439 0.3718 039.6% 2.57 (1.24, 5.33)
Subtotal (95% CI) 100.0% 1.83 (1.15, 2.89)
Heterogeneity: Tau2=0.00; chi2=1.43, df=3 (p=0.70); I2=0%
Test for overall effect: z=2.58 (p=0.01)
    0.01            0.1                 1                 10              100
Favours VA/TVA                                 Favours TA
Study or subgroup Log (odds ratio) SE Weight
Odds ratio
IV, random, 95% CI
Odds ratio
IV, random, 95% CI
5.1.1 LGD vs. HGD
Martinez et al.30 (pooled analysis) 0.0488 0.1324 60.6% 1.05 (0.81, 1.36)
Bonithon-Kopp et al.49 0.6206 0.3426 28.3% 1.86 (0.95, 3.64)
Jorgensen et al.9 (severe) 0.7419 0.6392 11.1% 2.10 (0.60, 7.35)
Subtotal (95% CI) 100.0% 1.33 (0.85, 2.09)
Heterogeneity: Tau2, 0.07; chi2, 3.33; df, 2 (p=0.19); I2, 40%
Test for overall effect: z, 1.25 (p=0.21)     0.01            0.1                 1                 10              100
Study or subgroup
Log 
(hazard ratio)
SE Weight
Hazard ratio
IV, random, 95% CI
Hazard ratio
IV, random, 95% CI
5.2.1 LGE vs. HGD
Huang et al.,35 2010 0.4762 0.2085 093.5% 1.61 (1.07, 2.42)
Bertario et al.,10 2003 1.1939 0.7911 006.5% 03.30 (0.70, 15.56)
Subtotal (95% CI) 100.0% 1.69 (1.14, 2.50)
Heterogeneity: Tau2, 0.00; chi2, 0.77; df, 1 (p=0.38); I2, 0%
Test for overall effect: z, 2.59 (p=0.010)
    0.01            0.1                 1                 10              100
Favours HGD                                   Favours LGD
Fig. 5. Forest plot for adenomas with high grade dysplasia as a risk factor for advanced neoplasia. CI, confidence interval.DH Yang et al. 
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1.05; 95% CI, 0.81 to 1.35), and a meta-analysis by Saini et al.
37 
has indicated that high-grade dysplasia was a significant risk 
factor for subsequent advanced adenoma (pooled RR, 1.84; 
95% CI, 0.53 to 8.93).
Does the risk of subsequent advanced neoplasia increase in pa-
tients with serrated polyps?
Patients with serrated polyps 10 mm in size or larger 
have an increased risk of subsequent advanced neoplasia.   
· Quality of evidence: very low 
· Level of agreement: completely agree (3%), generally 
agree (61%), partially agree (34%), generally disagree 
(3%), and totally disagree (0%)
Serrated polyps are a heterogeneous group of lesions char-
acterized by the glandular serration (that is, a “saw-toothed” 
architecture of the crypt epithelium).
64 Historically, polyps with 
serrated architectures were thought to be a single entity (hyper-
plastic polyps) and were considered indolent, non-neoplastic, 
hyperproliferative lesions. Recently, there has been a growing 
recognition that there are different types of serrated polyps, in-
cluding hyperplastic, sessile serrated adenomas, traditional 
serrated adenomas, and mixed adenomas, and that a small 
subset of these types may progress to invasive cancer through 
the novel “serrated pathway.”
65 CRC that develops via the ser-
rated pathway is frequently located in the right colon, has high 
levels of microsatellite instability, and is associated with a CpG 
island methylator phenotype and mutation of the BRAF onco-
gene.
66,67 
In the systematic literature review, electronic databases 
(MEDLINE and the Cochrane Library) entries from January 
2000 to September 2010 were searched to identify potentially 
relevant articles using “serrated” AND “polyp OR adenoma” 
as keywords. A total of 52 studies were found. Three observa-
tional studies assessed the risk of CRC in patients with serrated 
polyps ≥10 mm in size by assessing the coexistence of ad-
vanced neoplasia (Supplementary Table 6 online).
68-70 In the 
meta-analysis of these studies, the patients with serrated pol-
yps ≥10 mm in size had an increased risk of subsequent ad-
vanced neoplasia, with a pooled OR of 1.98 (95% CI, 1.24 to 
3.15) (Fig. 6).
A previous pooled analysis of two randomized chemopre-
vention trials has indicated that the incidence of overall colo-
rectal adenoma was not increased in surveillance colonosco-
pies performed 3 years after the removal of hyperplastic 
polyps.
71 Based on this result, the risk of subsequent colorectal 
tumors in patients with only hyperplastic polyps was regarded to 
be the same as that of average-risk individuals who have never 
been diagnosed with colorectal polyps.
15,17,21 However, Sch-
reiner et al.
69 have reported that the patients with right-sided, 
non-dysplastic serrated polyps, including hyperplastic polyps 
and sessile serrated adenomas, have an increased risk of syn-
chronous advanced adenomas (OR, 1.90; 95% CI, 1.33 to 2.70) 
and subsequent adenomas (OR, 3.14; 95% CI, 1.59 to 6.20). Lu 
et al.
72 have reported that a significant number of sessile serrat-
ed adenomas may not be accurately diagnosed in daily clini-
cal practice and that these entities have a risk of progression 
to CRC. In addition, Lim et al.
73 have reported that the pres-
ence of at least one hyperplastic polyp larger than 6 mm in ei-
ther the proximal or distal colon was associated with an in-
creased risk of advanced neoplasm (OR, 4.75; 95% CI, 2.30 
to 9.78). 
Locations of adenomas 
The association between adenoma distribution and the risk 
of subsequent advanced neoplasia has been recently evaluat-
ed in a pooled analysis
30 and three observational studies 
(Supplementary Table 7 online).
34,35,51 In all of these studies, 
the right colon was defined as all the segments proximal to 
the splenic flexure. The pooled OR of the risk for advanced 
neoplasia in the patients with any adenomas in the right co-
lon compared to the patients with adenomas only in the left 
colon was 1.73 (95% CI, 1.48 to 2.01) (Fig. 7). 
Recent studies have suggested that right-sided colon cancer 
can develop through the serrated pathway.
74,75 In addition, 
missed and recurrent adenomas are more likely to occur in the 
right colon.
76 Therefore, recent studies have reported that colo-
noscopy is less effective in preventing right-sided colon can-
cers.
77-79 However, right-sided colonic neoplasia was associated 
with specific patient characteristics, such as age and sex, and 
Study or subgroup Log (odds ratio) SE Weight
Odds ratio
IV, random, 95% CI
Odds ratio
IV, random, 95% CI
Schrener, 2010 0.2852 0.1820 34.6% 1.33 (0.93, 1.90)
Li et al.,70 2009 0.7178 0.2345 30.5% 2.05 (1.29, 3.25)
Hiraoka et al.,68 2010 1.0403 0.1785 34.9% 2.83 (1.99, 4.02)
Total (95% CI) 100.0% 1.98 (1.24, 3.15)
Heterogeneity: Tau2=0.13; chi2=8.81, df=2 (p=0.01); I2=77%
Test for overall effect: z=2.85 (p=0.004)     0.01            0.1                 1                 10              100
Favours large serrated polyps     Favours control
Fig. 6. Forest plot of the large (≥10 mm) serrated polyps at index colonoscopy as a risk factor for advanced neoplasia. CI, confidence interval.54  Clin Endosc 2012;45:44-61
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multiple environmental factors.
80-84 Furthermore, right colonic 
adenomas were quite prevalent, and approximately 2/3 of the 
patients with any colorectal adenomas were reported as having 
at least one right side colonic adenoma.
85 In the Delphi meetings, 
the level of agreement with the statement that adenomas locat-
ed in the right colon are a risk factor for advanced neoplasia 
was inconsistent. Therefore, it is only tentatively concluded that 
right colonic adenomas are a risk factor for subsequent ad-
vanced neoplasia, and additional evidence is needed. 
Patient age, sex, familial CRC history, smoking 
history and degree of obesity 
The association between the risk of subsequent advanced 
neoplasia and patient age has been evaluated in one pooled 
analysis
30 and six observational studies.
9,10,31,35,81,86 However, be-
cause these studies used different age group classifications, it 
was difficult to synthesize this information, and recommen-
dations could not be drawn (Supplementary Table 8 online). 
While a pooled analysis by Martinez et al.
30 has reported that 
the risk of subsequent advanced neoplasia increased with 
age, Chung et al.
36 have reported in a prospective Korean co-
hort study that patients aged 60 to 69 did not show a higher 
risk of subsequent advanced neoplasia than patients aged 50 to 
59 (HR, 1.51; 95% CI, 0.86 to 2.65). 
Several studies have assessed whether patient sex was as-
sociated with the risk of subsequent advanced neoplasia (Sup-
plementary Table 9 online).
9,30,31,34,36,86,87 Although the pooled 
analysis by Martinez et al.
30 has reported that the risk of subse-
quent advanced neoplasia was greater in males, a Korean pro-
spective cohort study showed no difference in the risk of ad-
vanced neoplasia between the sexes.
36 Therefore, the evidence 
supporting different postpolypectomy surveillance policies 
based on patient sex is thought to be insufficient (Fig. 8). 
Although a familial history of CRC was reported to have a 
positive association with the risk of subsequent advanced neo-
plasia in some studies,
32 a familial history of CRC was not as-
Study or subgroup Log (odds ratio) SE Weight
Odds ratio
IV, random, 95% CI
Odds ratio
IV, random, 95% CI
Jorgensen et al.,9 1995 0.1054 0.4139 03.2% 1.11 (0.49, 2.50)
Pinsky, 2009 0.1823 0.2069 12.6% 1.20 (0.80, 1.80)
Martinez et al.30 (pooled analysis) 0.3365 0.0838 76.9% 1.40 (1.19, 1.65)
Noshirwani et al.,31 2000 0.3920 0.3536 04.3% 1.48 (0.74, 2.96)
Laiyemo et al.,86 2009 0.6931 0.4250 03.0% 2.00 (0.87, 4.60)
Total (95% CI) 100.0% 1.38 (1.20, 1.59)
Heterogeneity: Tau2=0.00; chi2=1.56, df=4 (p=0.82); I2=0%
Test for overall effect: z=4.39 (p<0.0001)     0.01            0.1                 1                 10              100
Study or subgroup
Log 
(hazard ratio)
SE Weight
Hazard ratio
IV, random, 95% CI
Hazard ratio
IV, Fixed, 95% CI
Bertario et al.,10 2003 1.8718 0.7833 06.6% 06.50 (1.40, 30.18)
Yamaji et al.,87 2004 -0.105 0 0.2999 45.3% 0.90 (0.50, 1.62)
Chung et al.,36 2011 0 0.2913 48.0% 1.00 (0.56, 1.77)
Total (95% CI) 100.0% 1.08 (0.73, 1.60)
Heterogeneity: Tau2=5.69, df=2 (p=0.06); I2=65%
    0.01            0.1                 1                 10              100
Test for overall effect: z=0.38 (p=0.70) Favours female                                 Favours male
Fig. 8. Forest plot for the gender as a risk factor for advanced neoplasia. CI, confidence interval.
Study or subgroup Log (odds ratio) SE Weight
Odds ratio
IV, random, 95% CI
Odds ratio
IV, random, 95% CI
Martinez et al.30 (pooled analysis) 0.5188 0.0838 85.8% 1.68 (1.43, 1.98)
Pinsky et al.,34 2009 0.5878 0.2513 09.5% 1.80 (1.10, 2.95)
Bonithon-Kopp et al.49 0.9670 0.3575 04.7% 2.63 (1.31, 5.30)
Total (95% CI) 100.0% 1.73 (1.48, 2.01)
Heterogeneity: Tau2=0.00; chi2=1.52, df=2 (p=0.47); I2=0%
Test for overall effect: z=7.04 (p<0.00001)     0.01            0.1                 1                 10              100
Favours proximal adenomas   Favours distal adenomas
Fig. 7. Forest plot for the location of index polyps as a risk factor for advanced neoplasia. CI, confidence interval.DH Yang et al. 
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sociated with an increased risk of subsequent advanced ade-
noma in most studies (Supplementary Table 10 online).
10,30,36,86 
A meta-analysis of these studies showed a trend towards an 
increase, with a pooled OR of 1.20 (95% CI, 0.96 to 1.50), but 
this effect was not statistically significant (Fig. 9). In a Korean 
prospective cohort study, the risk of subsequent advanced 
neoplasia was unchanged in the presence of a familial history 
of CRC (adjusted HR, 1.00; 95% CI, 0.57 to 1.77).
36 
A limited number of studies have assessed the effects of smok-
ing and obesity on the risk of subsequent advanced neoplasia 
upon colonoscopic surveillance. In a pooled analysis by Marti-
nez et al.
30 and a Korean prospective cohort study, however, 
the risk of subsequent advanced neoplasia did not increase with 
smoking (Supplementary Table 11 online) or with the degree 
of obesity, as assessed by body mass index (Supplementary Ta-
ble 12 online).
36
High-risk groups for subsequent advanced colorectal 
neoplasia at postpolypectomy surveillance
It is well known that the risk of subsequent colorectal ade-
noma and advanced neoplasia is increased in patients with 
polyps compared to patients without polyps.
2,3,6-11 Identifying 
a high-risk group among postpolypectomy patients should 
thus be effective in establishing effective surveillance strategies 
and enhancing patient compliance to surveillance.
15,21 
Based on the results of the systematic literature reviews and 
a meta-analysis, patients with any of the following index colo-
noscopy findings had an increased risk of subsequent advanced 
neoplasia: 1) 3 or more adenomas, 2) any adenoma larger than 
10 mm, 3) any tubulovillous or villous adenoma, 4) any adeno-
ma with high-grade dysplasia, and 5) any serrated polyps larger 
than 10 mm. Therefore, patients who exhibit any of these find-
ings should be classified as being at high risk for subsequent 
advanced neoplasia for the purposes of postpolypectomy sur-
veillance (Table 2). 
The appropriate time interval for postpolypectomy 
surveillance colonoscopy
What is an appropriate time interval for postpolypectomy sur-
veillance colonoscopy in patients without a high-risk finding at 
the index colonoscopy? 
In patients without a high-risk finding at the index colo-
noscopy, surveillance colonoscopy should be performed 
five years after a high-quality index colonoscopy is admin-
istered by a qualified endoscopist. However, the surveil-
lance interval can be shortened if the quality of the index 
colonoscopy was not high or if a high-risk finding was 
observed in a colonoscopy prior to the index colonoscopy.
· Quality of evidence: low 
· Level of recommendation: weak 
· Level of agreement: completely agree (23%), generally 
agree (41%), partially agree (31%), generally disagree 
(5%), and totally disagree (0%)
In the 1990s and earlier, before there was sufficient evidence 
to recommend an appropriate postpolypectomy surveillance 
interval, surveillance colonoscopy was generally conducted on 
a yearly basis. The National Polyp Study was the first random-
ized controlled trial to address the question of an adequate 
postpolypectomy surveillance interval. In this study, 1,418 pa-
tients who had undergone removal of one or more adenomas 
Study or subgroup Log (odds ratio) SE Weight
Odds ratio
IV, random, 95% CI
Odds ratio
IV, random, 95% CI
Laiyemo et al.,86 2009 0 0.3536 9.8% 1.00 (0.50, 2.00)
Martinez et al.30 (pooled analysis) 0.1570 0.0852 84.8% 1.17 (0.99, 1.38)
Nusko et al.,32 2002 0.8416 0.4831 5.4% 2.32 (0.90, 5.98)
Total (95% CI) 100.0% 1.20 (0.96, 1.50)
Heterogeneity: Tau2=0.01; chi2=2.19, df=2 (p=0.34); I2=9%
Test for overall effect: z=1.56 (p=0.12)     0.01            0.1                 1                 10              100
Study or subgroup
Log 
(hazard ratio)
SE Weight
Hazard ratio
IV, random, 95% CI
Hazard ratio
IV, Fixed, 95% CI
Chung et al.,36 2011 0.131 0.4511 27.5% 1.14 (0.47, 2.76)
Bertario et al.,10 2003 0.2624 0.2776 72.5% 1.30 (0.75, 2.24)
Total (95% CI) 100.0% 1.25 (0.79, 1.99)
Heterogeneity: Tau2=0.00; chi2=0.06, df=1 (p=0.80); I2=0%     0.01            0.1                 1                 10              100
Test for overall effect: z=0.96 (p=0.34) Favours family history (+)   Favours family history (-)
Fig. 9. Forest plot for the family history of colorectal cancers as a risk factor for advanced neoplasia. CI, confidence interval.56  Clin Endosc 2012;45:44-61
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were randomized into a two-examination group (with a surveil-
lance colonoscopy at 1 year and 3 years) and a one-examina-
tion group (with a surveillance colonoscopy at 3 years). The 
percentage of patients with adenomas with advanced patho-
logical features was the same in both groups (3.3%). Therefore, 
an interval of 3 years between colonoscopic adenoma removal 
and a surveillance colonoscopy to detect advanced neoplasia 
was suggested.
6 
In a large rigid sigmoidoscopy cohort study published in 
1992, the patients with ≤10 mm tubular adenomas did not 
show an increased risk of subsequent CRC after polypectomy 
compared to the general population.
11 In the Funen adenoma 
follow-up study, postpolypectomy patients randomly received 
surveillance at either 2 years or 4 years to assess the influence 
of these surveillance intervals on the risk of new colorectal 
neoplasms after the removal of pedunculated or small sessile 
tubular and tubulovillous adenomas. The cumulative incidence 
of advanced neoplasia in the group that received postpolypec-
tomy surveillance at 4 years (5.2% [2.3% to 8.1%]) was not sig-
nificantly different from that of the group that received sur-
veillance at both 2 and 4 years (8.6% [3.8% to 13.3%]).
9 These 
results suggest that patients who have undergone removal of 
one or two tubular adenomas of ≤10 mm should be consid-
ered to have a relatively low risk of subsequent advanced neo-
plasia and that the first surveillance colonoscopy after polyp-
ectomy may be delayed for three years or longer in these 
patients.
Lieberman et al.
52 have described a randomized controlled 
trial of several intervals of surveillance colonoscopy after re-
moving small (<10 mm) adenomas. The patients with tubular 
adenomas <10 mm were randomly assigned by concealed al-
location to receive colonoscopic surveillance at 2 and 5 years 
(n=300) or at 5 years only (n=294). Both the groups had a 
similar risk of subsequent advanced neoplasia (4.9% for the 
5-year group and 6.4% for the 2- and 5-year group; p=0.55).
52 
In a recent Korean prospective cohort study, the 5-year cumu-
lative incidence rates of advanced adenoma in normal subjects 
(n=1,242) and in patients who had undergone removal of one 
or two small (<10 mm) tubular adenomas (n=671) were 2.4% 
and 2.0%, respectively. The risk of advanced neoplasia at 5 
years after the removal of one or two small tubular adenomas 
was not increased compared to that of the normal subjects 
(adjusted HR, 1.14; 95% CI, 0.61 to 2.17).
36 
Currently, the intervals suggested for postpolypectomy sur-
veillance colonoscopy are based on the findings from the in-
dex colonoscopy, i.e., the most recent high-quality colonos-
copy. Recently, Robertson et al.
88 have investigated the risk of 
clinically significant adenoma recurrence based on the results 
of 2 previous colonoscopies. This study was performed on pa-
tients with a qualifying adenoma at their first colonoscopy 
who then underwent second and third colonoscopies at 
roughly 3-year intervals. If the second examination showed no 
adenomas, then the results of the first examination added sig-
nificant information about the probability of high-risk find-
ings at the third examination (12.3% if the first examination 
had high-risk findings vs. 4.9% if the first examination had 
low-risk findings; p=0.015).
88 Similarly, Laiyemo et al.
86 have 
reported that the probability of detecting an advanced adeno-
ma in the third colonoscopy was 13.8% in the polyp preven-
tion trial participants with low-risk adenomas at the first colo-
noscopy and high-risk adenomas at the second colonoscopy 
and 11.9% in those with high-risk adenomas at the first colo-
noscopy and low-risk adenomas at the second colonoscopy. 
However, those authors also reported that the probability of 
detecting an advanced adenoma in the third colonoscopy was 
6.8% in the participants with high-risk adenomas at the first 
colonoscopy but no adenomas at the second colonoscopy, 
which was lower than the rate reported by Robertson et al.
88 
These results suggest that both the index colonoscopy and the 
earlier colonoscopies should be considered when determining 
the appropriate surveillance interval. However, there is no fur-
ther evidence to suggest an appropriate time interval for the 
third colonoscopy.
What is an appropriate time interval for postpolypectomy sur-
veillance colonoscopy in high-risk groups? 
In patients with a high risk of subsequent advanced neo-
plasia, surveillance colonoscopy should be performed three 
years after a high-quality index colonoscopy is administered 
by a qualified endoscopist. However, the surveillance in-
terval can be shortened if the quality of the index colo-
noscopy was low or based on the index colonoscopy find-
ings, the completeness of polyp removal, patient conditions, 
family history and medical history.
· Quality of evidence: low 
· Strength of a recommendation: weak 
· Level of agreement: completely agree (21%), generally 
agree (44%), partially agree (23%), generally disagree 
(10%), and totally disagree (3%)
Table 2. Patients with a High Risk of Subsequent Advanced Neo-
plasia at Postpolypectomy Surveillance Colonoscopy
Index colonoscopy findings related to an increased risk 
  of subsequent neoplasia, any of the followings:
1. Three or more adenomas
2. Any adenoma(s) larger than 10 mm
3. Any tubulovillous or villous adenoma(s)
4. Any adenoma(s) with high-grade dysplasia
5. Any serrated polyp(s) larger than 10 mmDH Yang et al. 
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Most of the high-quality studies that have evaluated the risk 
factors for subsequent advanced neoplasia are observational 
studies conducted on participants in polyp prevention trials. 
Because these studies were conducted after the National Pol-
yp Study and the Funen adenoma follow-up study, most of 
the polyp prevention trials have included a three- or four-
year surveillance interval.
10,30-32,34-36,49,51,87 Although the likeli-
hood of detecting advanced adenomas in a surveillance con-
ducted 3 or 4 years later was increased for the high-risk groups 
in these studies, the actual incidence of CRC was quite low. 
Therefore, three years may be suggested as an appropriate sur-
veillance interval. However, the patients who participated in 
the National Polyp Study and other clinical trials received a 
high-quality colonoscopy from expert endoscopists or were 
checked for missed polyps and complete polyp resection in an 
additional clearing colonoscopy. In addition, some chemopre-
vention trials have excluded patients with a familial history of 
CRC. In clinical practice, therefore, detailed information about 
the quality of the index colonoscopy, patient family history 
and medical history should be considered along with the find-
ings of the index colonoscopy to determine the optimal surveil-
lance interval.
Furthermore, it has not yet been determined whether the 
risk of subsequent advanced neoplasia increases in patients 
with two or more overlapping high-risk findings. In a large-
scale rigid sigmoidoscopy study by Atkin et al.,
11 the standard-
ized incidence ratio of CRC in the patients with a single high-
risk adenoma in the index sigmoidoscopy was 2.9 (95% CI, 1.8 
to 4.5), whereas that of the patients with multiple high-risk ad-
enomas increased to 6.6 (95% CI, 3.3 to 11.8). Noshirwani et 
al.
31 have reported that the probability of subsequent advanced 
adenomas in patients with three adenomas smaller than 10 
mm at the index colonoscopy was estimated to be 8.5%, where-
as the probability increased to 21.3% in those with three ade-
nomas, at least one of which was ≥10 mm. This study also esti-
mated that the probability of subsequent advanced adenoma 
at surveillance was 15.3% in the patients with four or more ad-
enomas <10 mm and 34.5% in those with four or more adeno-
mas and at least one ≥10 mm. These results suggest that over-
lapping high-risk findings further increase the risk of sub-
sequent advanced adenoma. However, this evidence is insu-
fficient to support any specific postpolypectomy surveillance 
guidelines. 
DISCUSSION
Because patients with colorectal adenomas are at increased 
risk for subsequent colorectal neoplasia compared to patients 
with no polyps, periodic postpolypectomy colonoscopic sur-
veillance is necessary.
2,3,6-11 The index colonoscopy findings 
associated with an increased risk of subsequent advanced neo-
plasia at surveillance include the following: 1) the presence of 3 
or more adenomas, 2) any adenomas ≥10 mm, 3) any tubulo-
villous or villous adenomas, 4) any adenomas with high-grade 
dysplasia, and 5) any serrated polyps ≥10 mm. It is suggested 
that patients with any of these conditions should be classified 
into an advanced neoplasia high-risk group at their subse-
quent postpolypectomy surveillance colonoscopies. 
Based on the literature review and evidence, it is recommend-
ed that colonoscopic surveillance in Korea be performed 3 
years after polypectomy in those patients with high-risk find-
ings and 5 years after in those patients without high-risk find-
ings.
However, several factors should be considered before deter-
mining the surveillance colonoscopy interval (Table 3). First, 
the index colonoscopy should reach the cecal base with ade-
quate bowel preparation. If the cecal intubation failed or if 
bowel preparation was inadequate during the index colonos-
copy, significant colorectal lesions may be missed, and a repeat 
colonoscopy is recommended.
89 Because the quality of the in-
dex colonoscopy may vary significantly among endoscopists, 
screening and surveillance colonoscopies should only be con-
ducted by qualified endoscopists.
90-92 If any polyps, especially 
adenomas with high-grade dysplasia, may have been incom-
pletely removed, the completeness of the resection should be 
confirmed by a repeat colonoscopy.
55,58-61 Finally, the surveil-
lance interval proposed in this guideline is applicable to asymp-
tomatic adults. The necessity of a diagnostic colonoscopy in 
any symptomatic patients should be assessed by a physician, re-
gardless of the recommended surveillance interval. In summa-
Table 3. Prerequisite to Determine the Surveillance Colonoscopy Interval Based on the Guideline
1..  The index colonoscopy should reach the cecal base with adequate bowel preparation. If the cecal intubation failed or if bowel preparation 
was inadequate during the index colonoscopy, significant colorectal lesions may be missed, and a repeat colonoscopy is recommended.
2..  Because the quality of the index colonoscopy may vary significantly among endoscopists, screening and surveillance colonoscopies should 
only be conducted by qualified endoscopists. 
3..  If any polyps, especially adenomas with high-grade dysplasia, may have been incompletely removed, the completeness of the resection 
should be confirmed by a repeat colonoscopy.
4..  The surveillance interval proposed in this guideline is applicable to asymptomatic adults. The necessity of a diagnostic colonoscopy in any 
symptomatic patients should be assessed by a physician, regardless of the recommended surveillance interval.58  Clin Endosc 2012;45:44-61
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ry, physicians should determine the appropriate surveillance 
colonoscopy intervals for patients on a case-by-case basis, con-
sidering the quality and bowel preparation status of the index 
colonoscopy, the completeness of the adenoma resection, and 
the patient’s general health, family history and medical history. 
Previous guidelines have suggested short surveillance inter-
vals of 1 to 3 years for patients with 10 or more adenomas. 
However, these recommendations have not been based on suf-
ficient evidence.
15,17-21 In patients with pathologically incom-
pletely resected polyps or polyps that were resected in piece-
meal fashion, by contrast, a follow-up colonoscopy within two 
to six months is recommended by most experts because of the 
risk of residual adenomatous lesion.
18-21 However, no specific 
time interval for the follow-up colonoscopy in these patients 
could be suggested in this guideline because there is insufficient 
evidence to determine an appropriate surveillance interval. 
There is also insufficient evidence to suggest an appropriate 
surveillance interval in patients who have undergone multiple 
colonoscopies before the index colonoscopy or who exhibit 
multiple high-risk findings.
This is the first postpolypectomy surveillance guideline pub-
lished for Korea. Because the Korean data on postpolypectomy 
surveillance were quite limited, many of these recommenda-
tions were made based on evidence from Western countries in 
which the health care environments are different from that of 
Korea. In particular, colonoscopy fees are lower in Korea than 
in Western countries; therefore, further cost-effectiveness anal-
ysis should be conducted using the results of colorectal polyp 
studies performed with Korean populations. Finally, it is em-
phasized that this guideline cannot address all clinical situa-
tions and thus cannot supersede clinical judgments that con-
sider the specific characteristics of individual patients. 
SUMMARY
1. Patients with three or more adenomas have an increased 
risk of subsequent advanced neoplasia.
2. Patients with an adenoma that is 1 cm or larger have an in-
creased risk of advanced neoplasia. In cases where tubulo-
villous or villous adenomas have been found in the index 
colonoscopy, the risk of detecting advanced neoplasia in a 
surveillance colonoscopy is increased compared with the 
risk in patients with non-villous tubular adenomas.
3. Patients with tubulovillous or villous adenomas have an in-
creased risk of advanced neoplasia.
4. Patients with high-grade dysplasia adenomas have an in-
creased risk of subsequent advanced neoplasia.
5. Patients with serrated polyps 10 mm in size or larger have 
an increased risk of subsequent advanced neoplasia.
6. Patients should be considered at high risk for subsequent 
advanced neoplasia at surveillance colonoscopy when one 
or more of the following conditions have been detected at 
index colonoscopy: 1) 3 or more adenomas, 2) any adeno-
ma larger than 10 mm, 3) any tubulovillous or villous ade-
noma, 4) any adenoma with high-grade dysplasia, and 5) 
any serrated polyps larger than 10 mm..
7. In patients without a high-risk finding at the index colo-
noscopy, surveillance colonoscopy should be performed 
five years after a high-quality index colonoscopy is admin-
istered by a qualified endoscopist. However, the surveil-
lance interval can be shortened if the quality of the index 
colonoscopy was not high or if a high-risk finding was ob-
served in a colonoscopy prior to the index colonoscopy.
8. In patients with a high risk of subsequent advanced neo-
plasia, surveillance colonoscopy should be performed three 
years after a high-quality index colonoscopy is adminis-
tered by a qualified endoscopist. However, the surveillance 
interval can be shortened if the quality of the index colo-
noscopy was low or based on the index colonoscopy find-
ings, the completeness of polyp removal, patient condi-
tions, family history and medical history.
Conflicts of Interest
The authors have no financial conflicts of interest.
Acknowledgments
We extend profound thanks to Professor Chae, Hiun Suk (The Catholic 
University of Korea College of Medicine), Professor Han, Dong Soo (Han-
yang University Guri Hospital), and Professor Jeen, Yoon Tae (Korea Uni-
versity College of Medicine) who gave unsparing advice regarding the de-
velopment of these guidelines for postpolypectomy surveillance. 
We also give great thanks to the Korean Association of Internal Medicine 
and Korean Physicians Association for their agreement with final version of 
these guidelines. 
This study was initiated with the support of the Korean Society of Gastro-
enterology, the Korean Society of Gastrointestinal Endoscopy, and the Ko-
rean Association for the Study of Intestinal Disease. This study was sup-
ported by a grant for the Korean Health Technology R&D Project with the 
Ministry for Health and Welfare of the Republic of Korea (A102065-23).
REFERENCES
1. Thiis-Evensen E, Hoff GS, Sauar J, Langmark F, Majak BM, Vatn MH. 
Population-based surveillance by colonoscopy: effect on the incidence 
of colorectal cancer. Telemark Polyp Study I. Scand J Gastroenterol 
1999;34:414-420.
2. Citarda F, Tomaselli G, Capocaccia R, Barcherini S, Crespi M; Italian 
Multicentre Study Group. Efficacy in standard clinical practice of colo-
noscopic polypectomy in reducing colorectal cancer incidence. Gut 
2001;48:812-815.
3. Loeve F, van Ballegooijen M, Snel P, Habbema JD. Colorectal cancer 
risk after colonoscopic polypectomy: a population-based study and lit-
erature search. Eur J Cancer 2005;41:416-422.
4. Stryker SJ, Wolff BG, Culp CE, Libbe SD, Ilstrup DM, MacCarty RL. 
Natural history of untreated colonic polyps. Gastroenterology 
1987;93:1009-1013.
5. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer 
by colonoscopic polypectomy. The National Polyp Study Workgroup. DH Yang et al. 
  59
N Engl J Med 1993;329:1977-1981.
6. Winawer SJ, Zauber AG, O’Brien MJ, et al. Randomized comparison 
of surveillance intervals after colonoscopic removal of newly diag-
nosed adenomatous polyps. The National Polyp Study Workgroup. N 
Engl J Med 1993;328:901-906.
7. Meagher AP, Stuart M. Does colonoscopic polypectomy reduce the in-
cidence of colorectal carcinoma? Aust N Z J Surg 1994;64:400-404.
8. Lund JN, Scholefield JH, Grainge MJ, et al. Risks, costs, and compli-
ance limit colorectal adenoma surveillance: lessons from a randomised 
trial. Gut 2001;49:91-96.
9. Jorgensen OD, Kronborg O, Fenger C. A randomized surveillance 
study of patients with pedunculated and small sessile tubular and tu-
bulovillous adenomas. The Funen Adenoma Follow-up Study. Scand J 
Gastroenterol 1995;30:686-692.
10. Bertario L, Russo A, Sala P, et al. Predictors of metachronous colorec-
tal neoplasms in sporadic adenoma patients. Int J Cancer 2003;105:82-
87.
11. Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer 
after excision of rectosigmoid adenomas. N Engl J Med 1992;326:658-
662.
12. The National Health Insurance Corporation. National Health Insur-
ance Statistical Yearbook for 2009 [Internet]. Seoul: The National Health 
Insurance Corporation; c2011 [cited 2011 Dec 17]. Available from: http://
www.nhic.or.kr.
13. The National Health Insurance Corporation. Trend of studies about 
economic evaluation of the cancer screening programs [Internet]. 
Seoul: The National Health Insurance Corporation; c2011 [cited 2011 
Dec 17]. Available from: http://www.nhic.or.kr.
14. Rapuri S, Spencer J, Eckels D. Importance of postpolypectomy surveil-
lance and postpolypectomy compliance to follow-up screening: review 
of literature. Int J Colorectal Dis 2008;23:453-459.
15. Arditi C, Peytremann-Bridevaux I, Burnand B, et al. Appropriateness 
of colonoscopy in Europe (EPAGE II). Screening for colorectal cancer. 
Endoscopy 2009;41:200-208.
16. Bond JH. Polyp guideline: diagnosis, treatment, and surveillance for 
patients with colorectal polyps. Practice Parameters Committee of the 
American College of Gastroenterology. Am J Gastroenterol 2000;95: 
3053-3063.
17. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal 
cancer screening and surveillance in moderate and high risk groups 
(update from 2002). Gut 2010;59:666-689.
18. Davila RE, Rajan E, Baron TH, et al. ASGE guideline: colorectal cancer 
screening and surveillance. Gastrointest Endosc 2006;63:546-557.
19. Levin B, Lieberman DA, McFarland B, et al. Screening and surveil-
lance for the early detection of colorectal cancer and adenomatous 
polyps, 2008: a joint guideline from the American Cancer Society, the 
US Multi-Society Task Force on Colorectal Cancer, and the American 
College of Radiology. Gastroenterology 2008;134:1570-1595.
20. Schmiegel W, Pox C, Arnold D, Porschen R, Rodel C, Reinacher-Schick 
A. Colorectal carcinoma: the management of polyps, (neo)adjuvant 
therapy, and the treatment of metastases. Dtsch Arztebl Int 2009;106:843-
848.
21. Winawer SJ, Zauber AG, Fletcher RH, et al. Guidelines for colonosco-
py surveillance after polypectomy: a consensus update by the US Multi-
Society Task Force on Colorectal Cancer and the American Cancer So-
ciety. Gastroenterology 2006;130:1872-1885.
22. Jung KW, Park S, Kong HJ, et al. Cancer statistics in Korea: incidence, 
mortality and survival in 2006-2007. J Korean Med Sci 2010;25:1113-
1121.
23. Park DI, Kim YH, Kim HS, et al. Diagnostic yield of advanced colorec-
tal neoplasia at colonoscopy, according to indications: an investigation 
from the Korean Association for the Study of Intestinal Diseases (KA-
SID). Endoscopy 2006;38:449-455.
24. Lee BH, Jeong SY. Korean national recommendation guidelines on 
screening and surveillance for early detection of colorectal cancers. J Ko-
rean Med Assoc 2002;45:981-991.
25. Korean Statistical Information Service. Population Projections for Ko-
rea: 2005-2050 (Based on the 2005 Census) [Internet]. Daejeon: Statis-
tics Korea; c2010 [cited 2011 Dec 17]. Available from: http://kosis.kr.
26. Ministry of Health and Walfare. The quality guidelines of colorectal 
cancer screening [Internet]. Seoul: Ministry of Health and Walfare; 
c2008 [cited 2011 Dec 17]. Available from: http://www.mw.go.kr/.
27. Zhang J, Yu KF. What’s the relative risk? A method of correcting the 
odds ratio in cohort studies of common outcomes. JAMA 1998;280: 
1690-1691.
28. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consen-
sus on rating quality of evidence and strength of recommendations. 
BMJ 2008;336:924-926.
29. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and 
strength of recommendations. BMJ 2004;328:1490.
30. Martinez ME, Baron JA, Lieberman DA, et al. A pooled analysis of ad-
vanced colorectal neoplasia diagnoses after colonoscopic polypectomy. 
Gastroenterology 2009;136:832-841.
31. Noshirwani KC, van Stolk RU, Rybicki LA, Beck GJ. Adenoma size 
and number are predictive of adenoma recurrence: implications for 
surveillance colonoscopy. Gastrointest Endosc 2000;51(4 Pt 1):433-437.
32. Nusko G, Mansmann U, Kirchner T, Hahn EG. Risk related surveil-
lance following colorectal polypectomy. Gut 2002;51:424-428.
33. Kim JB, Han DS, Lee HL, et al. The recurrence rate of colon polyp after 
polypectomy and the interval of surveillance colonoscopy: predictors 
of early development of advanced polyp. Korean J Gastroenterol 2004; 
44:77-83.
34. Pinsky PF, Schoen RE, Weissfeld JL, et al. The yield of surveillance 
colonoscopy by adenoma history and time to examination. Clin Gas-
troenterol Hepatol 2009;7:86-92.
35. Huang Y, Gong W, Su B, et al. Recurrence and surveillance of colorec-
tal adenoma after polypectomy in a southern Chinese population. J 
Gastroenterol 2010;45:838-845.
36. Chung SJ, Kim YS, Yang SY, et al. Five-year risk for advanced colorec-
tal neoplasia after initial colonoscopy according to the baseline risk 
stratification: a prospective study in 2452 asymptomatic Koreans. Gut 
2011;60:1537-1543.
37. Saini SD, Kim HM, Schoenfeld P. Incidence of advanced adenomas at 
surveillance colonoscopy in patients with a personal history of colon 
adenomas: a meta-analysis and systematic review. Gastrointest Endosc 
2006;64:614-626.
38. Chung CS, Yoon JS, Joh YG, et al. Colonoscopic missing rate of colorec-
tal polyps. Korean J Gastrointest Endosc 2004;28:179-182.
39. Choi KY, Lee BI, Lee SY, et al. Colonoscopic miss-rate of colorectal 
polyp and adenoma. Korean J Gastrointest Endosc 2003;26:199-204.
40. Park SY, Moon W, Park SJ, et al. The colonoscopic miss rates of 
colorectal polyps as determined by a polypectomy. Korean J Gastroin-
test Endosc 2008;36:132-137.
41. Kim JH, Kim YS, Cheon JH, et al. Influence of the insertion time and 
number of polyps on miss rate in colonoscopy. Scand J Gastroenterol 
2011;46:634-639.
42. Heresbach D, Barrioz T, Lapalus MG, et al. Miss rate for colorectal 
neoplastic polyps: a prospective multicenter study of back-to-back 
video colonoscopies. Endoscopy 2008;40:284-290.
43. Hixson LJ, Fennerty MB, Sampliner RE, Garewal HS. Prospective 
blinded trial of the colonoscopic miss-rate of large colorectal polyps. 
Gastrointest Endosc 1991;37:125-127.
44. Ben-Horin S, Bar-Meir S, Avidan B. The impact of colon cleanliness 
assessment on endoscopists’ recommendations for follow-up colonos-
copy. Am J Gastroenterol 2007;102:2680-2685.
45. Kang MS, Park DI, Park JH, et al. A survey on the interval of post-pol-
ypectomy surveillance colonoscopy. Korean J Gastrointest Endosc 
2006;33:339-345.
46. Hisabe T, Tsuda S, Matsui T, Iwashita A. Natural history of small 
colorectal protuberant adenomas. Dig Endosc 2010;22 Suppl 1:S43-S46.60  Clin Endosc 2012;45:44-61
Postpolypectomy Surveillance Guidelines
47. Hoff G, Foerster A, Vatn MH, Sauar J, Larsen S. Epidemiology of pol-
yps in the rectum and colon. Recovery and evaluation of unresected 
polyps 2 years after detection. Scand J Gastroenterol 1986;21:853-862.
48. Hofstad B, Vatn MH, Andersen SN, et al. Growth of colorectal polyps: 
redetection and evaluation of unresected polyps for a period of three 
years. Gut 1996;39:449-456.
49. Bonithon-Kopp C, Piard F, Fenger C, et al. Colorectal adenoma char-
acteristics as predictors of recurrence. Dis Colon Rectum 2004;47:323-
333.
50. van Stolk RU, Beck GJ, Baron JA, Haile R, Summers R. Adenoma 
characteristics at first colonoscopy as predictors of adenoma recur-
rence and characteristics at follow-up. The Polyp Prevention Study 
Group. Gastroenterology 1998;115:13-18.
51. Martinez ME, Sampliner R, Marshall JR, Bhattacharyya AK, Reid ME, 
Alberts DS. Adenoma characteristics as risk factors for recurrence of 
advanced adenomas. Gastroenterology 2001;120:1077-1083.
52. Lieberman DA, Weiss DG, Harford WV, et al. Five-year colon surveil-
lance after screening colonoscopy. Gastroenterology 2007;133:1077-
1085.
53. Laiyemo AO, Murphy G, Albert PS, et al. Postpolypectomy colonosco-
py surveillance guidelines: predictive accuracy for advanced adenoma 
at 4 years. Ann Intern Med 2008;148:419-426.
54. Nivatvongs S, Snover DC, Fang DT. Piecemeal snare excision of large 
sessile colon and rectal polyps: is it adequate? Gastrointest Endosc 
1984;30:18-20.
55. Seo GJ, Sohn DK, Han KS, et al. Recurrence after endoscopic piecemeal 
mucosal resection for large sessile colorectal polyps. World J Gastroen-
terol 2010;16:2806-2811.
56. Saito Y, Fukuzawa M, Matsuda T, et al. Clinical outcome of endoscopic 
submucosal dissection versus endoscopic mucosal resection of large 
colorectal tumors as determined by curative resection. Surg Endosc 
2010;24:343-352.
57. Seitz U, Bohnacker S, Seewald S, Thonke F, Soehendra N. Long-term re-
sults of endoscopic removal of large colorectal adenomas. Endoscopy 
2003;35:S41-S44.
58. Walsh RM, Ackroyd FW, Shellito PC. Endoscopic resection of large ses-
sile colorectal polyps. Gastrointest Endosc 1992;38:303-309.
59. Zlatanic J, Waye JD, Kim PS, Baiocco PJ, Gleim GW. Large sessile colon-
ic adenomas: use of argon plasma coagulator to supplement piecemeal 
snare polypectomy. Gastrointest Endosc 1999;49:731-735.
60. Brooker JC, Saunders BP, Shah SG, Williams CB. Endoscopic resection 
of large sessile colonic polyps by specialist and non-specialist endosco-
pists. Br J Surg 2002;89:1020-1024.
61. Conio M, Repici A, Demarquay JF, Blanchi S, Dumas R, Filiberti R. EMR 
of large sessile colorectal polyps. Gastrointest Endosc 2004;60:234-241.
62. Hwang ST, Cho YK, Park JH, et al. Relationship of non-alcoholic fatty 
liver disease to colorectal adenomatous polyps. J Gastroenterol Hepa-
tol 2010;25:562-567.
63. Yang G, Zheng W, Sun QR, et al. Pathologic features of initial adenomas 
as predictors for metachronous adenomas of the rectum. J Natl Cancer 
Inst 1998;90:1661-1665.
64. Terdiman JP, McQuaid KR. Surveillance guidelines should be updated 
to recognize the importance of serrated polyps. Gastroenterology 2010; 
139:1444-1447.
65. Leggett B, Whitehall V. Role of the serrated pathway in colorectal can-
cer pathogenesis. Gastroenterology 2010;138:2088-2100.
66. Arain MA, Sawhney M, Sheikh S, et al. CIMP status of interval colon 
cancers: another piece to the puzzle. Am J Gastroenterol 2010;105: 
1189-1195.
67. Sawhney MS, Farrar WD, Gudiseva S, et al. Microsatellite instability in 
interval colon cancers. Gastroenterology 2006;131:1700-1705.
68. Hiraoka S, Kato J, Fujiki S, et al. The presence of large serrated polyps 
increases risk for colorectal cancer. Gastroenterology 2010;139:1503-
1510, 1510.e1-e3.
69. Schreiner MA, Weiss DG, Lieberman DA. Proximal and large hyper-
plastic and nondysplastic serrated polyps detected by colonoscopy are 
associated with neoplasia. Gastroenterology 2010;139:1497-1502.
70. Li D, Jin C, McCulloch C, et al. Association of large serrated polyps 
with synchronous advanced colorectal neoplasia. Am J Gastroenterol 
2009;104:695-702.
71. Bensen SP, Cole BF, Mott LA, Baron JA, Sandler RS, Haile R. Colorec-
tal hyperplastic polyps and risk of recurrence of adenomas and hyper-
plastic polyps. Polyps Prevention Study. Lancet 1999;354:1873-1874.
72. Lu FI, van Niekerk de W, Owen D, Tha SP, Turbin DA, Webber DL. 
Longitudinal outcome study of sessile serrated adenomas of the col-
orectum: an increased risk for subsequent right-sided colorectal carci-
noma. Am J Surg Pathol 2010;34:927-934.
73. Lim HM, Kim ER, Kim JY, et al. Association between non-diminutive 
hyperplastic polyps and synchronous advanced colorectal neoplasms. 
Digestion 2011;83:54-59.
74. Laiyemo AO, Doubeni C, Sanderson AK 2nd, et al. Likelihood of missed 
and recurrent adenomas in the proximal versus the distal colon. Gastro-
intest Endosc 2011;74:253-261.
75. Iacopetta B. Are there two sides to colorectal cancer? Int J Cancer 2002; 
101:403-408.
76. Urso E, Pucciarelli S, Agostini M, et al. Proximal colon cancer in patients 
aged 51-60 years of age should be tested for microsatellites instability. A 
comment on the Revised Bethesda Guidelines. Int J Colorectal Dis 2008; 
23:801-806.
77. Baxter NN, Goldwasser MA, Paszat LF, Saskin R, Urbach DR, Raben-
eck L. Association of colonoscopy and death from colorectal cancer. Ann 
Intern Med 2009;150:1-8.
78. Brenner H, Chang-Claude J, Seiler CM, Rickert A, Hoffmeister M. Pro-
tection from colorectal cancer after colonoscopy: a population-based, 
case-control study. Ann Intern Med 2011;154:22-30.
79. Yoshida D, Kono S, Moore MA, et al. Colorectal polypectomy and risk 
of colorectal cancer by subsite: the Fukuoka Colorectal Cancer study. 
Jpn J Clin Oncol 2007;37:597-602.
80. Kim YG, Jang BI, Kim TN. A matched case-control study of a novel ac-
id-pump antagonist and proton-pump inhibitor for the treatment of iat-
rogenic ulcers caused by endoscopic submucosal dissection. Gut Liver 
2010;4:25-30.
81. Yamaji Y, Mitsushima T, Ikuma H, et al. Right-side shift of colorectal ad-
enomas with aging. Gastrointest Endosc 2006;63:453-458.
82. Schoenfeld P, Cash B, Flood A, et al. Colonoscopic screening of aver-
age-risk women for colorectal neoplasia. N Engl J Med 2005;352:2061-
2068.
83. Ferretti G, Felici A, Cognetti F, Mandala M. Is there a right-sided shift 
for colorectal cancer in women compared with men? Cancer Epidemiol 
Biomarkers Prev 2006;15:1054.
84. Rabeneck L, Davila JA, El-Serag HB. Is there a true “shift” to the right 
colon in the incidence of colorectal cancer? Am J Gastroenterol 2003; 
98:1400-1409.
85. Park SY, Kim BC, Shin SJ, Lee SK, Kim TI, Kim WH. Proximal shift in 
the distribution of adenomatous polyps in Korea over the past ten years. 
Hepatogastroenterology 2009;56:677-681.
86. Laiyemo AO, Pinsky PF, Marcus PM, et al. Utilization and yield of sur-
veillance colonoscopy in the continued follow-up study of the polyp 
prevention trial. Clin Gastroenterol Hepatol 2009;7:562-567.
87. Yamaji Y, Mitsushima T, Ikuma H, et al. Incidence and recurrence 
rates of colorectal adenomas estimated by annually repeated colonos-
copies on asymptomatic Japanese. Gut 2004;53:568-572.
88. Robertson DJ, Burke CA, Welch HG, et al. Using the results of a base-
line and a surveillance colonoscopy to predict recurrent adenomas with 
high-risk characteristics. Ann Intern Med 2009;151:103-109.
89. Lebwohl B, Kastrinos F, Glick M, Rosenbaum AJ, Wang T, Neugut AI. 
The impact of suboptimal bowel preparation on adenoma miss rates and 
the factors associated with early repeat colonoscopy. Gastrointest Endosc 
2011;73:1207-1214.
90. Barclay RL, Vicari JJ, Doughty AS, Johanson JF, Greenlaw RL. Colono-DH Yang et al. 
  61
scopic withdrawal times and adenoma detection during screening 
colonoscopy. N Engl J Med 2006;355:2533-2541.
91. Chen SC, Rex DK. Endoscopist can be more powerful than age and male 
gender in predicting adenoma detection at colonoscopy. Am J Gastroen-
terol 2007;102:856-861.
92. Baxter NN, Sutradhar R, Forbes SS, Paszat LF, Saskin R, Rabeneck L. 
Analysis of administrative data finds endoscopist quality measures asso-
ciated with postcolonoscopy colorectal cancer. Gastroenterology 2011; 
140:65-72.